Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study-Reference-Cited by-同舟云学术

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

Published:2013-10 Issue:11 Volume:14 Page:1129-1140
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dimopoulos Meletios,Siegel David S,Lonial Sagar,Qi Junyuan,Hajek Roman,Facon Thierry,Rosinol Laura,Williams Catherine,Blacklock Hilary,Goldschmidt Hartmut,Hungria Vania,Spencer Andrew,Palumbo Antonio,Graef Thorsten,Eid Joseph E,Houp Jennifer,Sun Linda,Vuocolo Scott,Anderson Kenneth C

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. Management of relapsed and relapsed/refractory multiple myeloma;Laubach;J Natl Compr Canc Netw,2011

2. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy;Carew;Cancer Lett,2008

3. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications;Mitsiades;Proc Natl Acad Sci USA,2004

4. Pomalidomide: first global approval;Elkinson;Drugs,2013

5. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib;Richardson;Blood,2013

Cited by 209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction;International Journal of Molecular Sciences;2024-08-16

2. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives;Experimental Hematology & Oncology;2024-04-23

3. Multiple Myeloma;Comprehensive Hematology and Stem Cell Research;2024

4. Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review;Life;2023-11-27

5. A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy;European Journal of Medicinal Chemistry;2023-11